Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

Απλή σελίδα τεκμηρίου
dc.contributor.authorNikas, S. N.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorAlamanos, Y.en
dc.contributor.authorPapadopoulos, C. G.en
dc.contributor.authorVenetsanopoulou, A. I.en
dc.contributor.authorGeorgiadis, A. N.en
dc.contributor.authorDrosos, A. A.en
dc.date.accessioned2015-11-24T19:20:23Z
dc.date.available2015-11-24T19:20:23Z
dc.identifier.issn0003-4967-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22034
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAntibodies, Monoclonal/*administration & dosage/adverse effects/therapeutic useen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntirheumatic Agents/*administration & dosage/adverse effects/therapeutic useen
dc.subjectArthritis, Rheumatoid/*drug therapy/immunology/physiopathologyen
dc.subjectBlood Sedimentationen
dc.subjectC-Reactive Protein/analysisen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHealth Status Indicatorsen
dc.subjectHumansen
dc.subjectJoints/physiopathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPlatelet Counten
dc.subjectTreatment Outcomeen
dc.subjectTumor Necrosis Factor-alpha/antagonists & inhibitorsen
dc.titleEfficacy and safety of switching from infliximab to adalimumab: a comparative controlled studyen
heal.abstractOBJECTIVE: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. METHODS: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor alpha inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. RESULTS: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months' adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study-two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study-one because of lack of efficacy and two owing to side effects. CONCLUSION: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1136/ard.2005.039099-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15975964-
heal.identifier.secondaryhttp://ard.bmj.com/content/65/2/257-
heal.journalNameAnn Rheum Disen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ